TY - JOUR
KW - Humans
KW - *Glycopyrrolate/adverse effects
KW - Retrospective Studies
KW - *Pulmonary Disease, Chronic Obstructive/diagnosis/drug therapy/epidemiology
KW - Muscarinic Antagonists/adverse effects
KW - England
KW - COPD dual therapy
KW - LABA/LAMA new users
KW - comparative effectiveness
KW - exacerbations
KW - Healthcare resource utilization
KW - single-inhaler dual therapy
AU - G. Requena
AU - A. Czira
AU - V. Banks
AU - R. Wood
AU - T. Tritton
AU - C. Castillo
AU - J. Yeap
AU - R. Wild
AU - C. Compton
AU - K. Rothnie
AU - F. Herth
AU - J. Quint
AU - A. Ismaila
AD - GSK, R&D Global Medical, Brentford, Middlesex, UK.
Real-World Evidence, Adelphi Real World, Bollington, Cheshire, UK.
Department of Pneumology and Critical Care Medicine, Thoraxklinik, University of Heidelberg and Translational Lung Research Center Heidelberg, Heidelberg, Germany.
National Heart and Lung Institute, Imperial College London, London, UK.
Value Evidence and Outcomes, GSK, Collegeville, PA, USA.
Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.
AN - 37731774
BT - Int J Chron Obstruct Pulmon Dis
C2 - PMC10508247
DO - 10.2147/copd.s408688
DP - NLM
ET - 2023/09/21
LA - eng
N1 - 1178-2005
Requena, Gema
Orcid: 0000-0002-1889-6656
Czira, Alexandrosz
Orcid: 0000-0002-3395-6186
Banks, Victoria
Orcid: 0000-0002-0087-7641
Wood, Robert
Orcid: 0000-0002-6977-435x
Tritton, Theo
Castillo, Catherine
Orcid: 0000-0002-7204-6169
Yeap, Jie
Wild, Rosie
Orcid: 0000-0002-9963-6441
Compton, Chris
Orcid: 0000-0002-7564-5343
Rothnie, Kieran J
Orcid: 0000-0003-4279-1624
Herth, Felix J F
Orcid: 0000-0002-7638-2506
Quint, Jennifer K
Orcid: 0000-0003-0149-4869
Ismaila, Afisi S
Orcid: 0000-0002-2876-8308
Journal Article
New Zealand
Int J Chron Obstruct Pulmon Dis. 2023 Sep 15;18:2039-2054. doi: 10.2147/COPD.S408688. eCollection 2023.
PY - 2023
SN - 1176-9106 (Print)1176-9106
SP - 2039
EP - 2054
T2 - Int J Chron Obstruct Pulmon Dis
TI - Comparative Effectiveness of Umeclidinium/Vilanterol versus Indacaterol/Glycopyrronium on Moderate-to-Severe Exacerbations in Patients with Chronic Obstructive Pulmonary Disease in Clinical Practice in England
VL - 18
ER -